Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy

Long-term survival benefit has been noticed in non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs), such as PD-1 inhibitors. However, it is still controversial whether patients with EGFR-activating mutations may benefit from ICIs. Recently, in stage IIIA NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Qian, Zhang, Xue, Ma, Qiang, Luo, Nuo, Liu, Zhulin, Wang, Renyuan, He, Yong, Li, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902042/
https://www.ncbi.nlm.nih.gov/pubmed/35273908
http://dx.doi.org/10.3389/fonc.2022.765997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902042/
https://www.ncbi.nlm.nih.gov/pubmed/35273908
http://dx.doi.org/10.3389/fonc.2022.765997

Ejemplares similares